<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594437</url>
  </required_header>
  <id_info>
    <org_study_id>TCN-202-001</org_study_id>
    <nct_id>NCT01594437</nct_id>
  </id_info>
  <brief_title>Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody</brief_title>
  <official_title>Phase 1 Study of TCN-202 (Human Anti-Cytomegalovirus Monoclonal Antibody) in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theraclone Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theraclone Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety profile in healthy adult volunteers of
      single or multiple intravenous administrations of TCN-202 as compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human cytomegalovirus (HCMV) disease remains an unmet medical need: In the US, the estimated
      prevalence of congenital HCMV infection is ~1% and is one of the leading causes of permanent
      hearing loss and neurological deficits in children. In immunocompromised individuals such as
      transplant recipients it can cause serious life-threatening disease and may significantly
      increase the risk of graft rejection. As existing therapies for HCMV can have serious side
      effects, there remains a medical need for safe and effective treatment of HCMV disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>60 days post infusion</time_frame>
    <description>Adverse events will be determined by physical examinations, vital signs, serial electrocardiograms, and clinical laboratory abnormalities (hematology, chemistry, and urinalysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak serum concentration (Cmax) of TCN-202</measure>
    <time_frame>1 day post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop anti-TCN-202 anti-drug antibodies (immunogenicity)</measure>
    <time_frame>60 days post infusion</time_frame>
    <description>Immunogenicity will be assessed based on induction of TCN-202 anti-drug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve (AUC) of TCN-202</measure>
    <time_frame>60 days post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration (Tmax) of TCN-202</measure>
    <time_frame>1 day post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>TCN-202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TCN-202</intervention_name>
    <description>Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.</description>
    <arm_group_label>TCN-202</arm_group_label>
    <other_name>Human Anti-Cytomegalovirus Monoclonal Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One or two doses administered by intravenous infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Sodium chloride for Injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteers

          -  Normal lab tests

        Exclusion Criteria:

          -  Prior treatment with monoclonal antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Al-Ibrahim, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Clinical Pharmacology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

